SAN DIEGO--(BUSINESS WIRE)--Concurrent with the annual European Human Genetics Conference in Nice, France, Illumina, Inc. (NASDAQ:ILMN) announced today that IntegraGen SA, a personalized healthcare company focused on the development and commercialization of molecular diagnostic tests for complex diseases and provider of genetic services, has received Illumina Certified Service Provider (CSPro™) certification for GoldenGate® and Infinium® genotyping technologies.
Illumina, a San Diego-based company, is a leading developer, manufacturer, and marketer of next-generation life science tools and integrated systems for the analysis of genetic variation and biological function. The GoldenGate assay is Illumina’s first array-based platform that combines high-sample throughput, high multiplexing, and single-site CpG resolution for DNA methylation profiling. The Infinium Whole-Genome Genotyping BeadArray™ solution offers single or multi-sample BeadChip formats and high-density architecture with the flexibility to add additional custom SNP Assays.
“IntegraGen is a company dedicated to offering high-quality services to other research institutes, either private or academic, and is the first laboratory in France to achieve CSPro certification for GoldenGate and Infinium Genotyping,” said Karen Possemato, Illumina’s Director of Corporate Marketing. “By becoming a member of CSPro, they have further demonstrated their commitment to the life science community, providing delivery of the highest-quality data available for genetic analysis applications.”
Emmanuel Martin, IntegraGen’s Director of Services and Arrays, said: “IntegraGen is proud of its ability to leverage core competencies and provide genetic services to the research community. Receiving Illumina CSPro certification is an endorsement of both Illumina and IntegraGen’s commitment to quality, and provides our customers with even greater confidence in our ability meet their needs.”
As a customer of IntegraGen, Jessica Zucman-Rossi, M.D., Ph.D., has been using Illumina technology in a pilot study for loss of heterozygosity (LOH) analysis in liver tumors at the Human Polymorphism Study Center (CEPH) in Paris. “We also chose Illumina technology to test for promoter methylation in liver tumors because there were a large number of genes available for testing with this system, and the ability to quantify methylation levels is a real advantage. My team was able to analyze a large number of samples in each experiment, and the time taken to generate results was short, generating a large amount of data.” She added, “The results we attained were excellent, achieving methylation profiling of 96 tumor samples on more than 1,500 CpG. The data are robust, and we are currently preparing a second series of samples.”
About Illumina CSPro
Illumina CSPro is a collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CSPros undergo a rigorous two-phase certification process that includes minimum data generation, data certification and on-site audit of the facility and processes. For more information about the CSPro program, please visit www.illumina.com/cspro.
IntegraGen is a pioneer in the field of predictive healthcare. The company uses its unique genomic analysis expertise to identify genes associated with complex diseases and commercializes molecular diagnostic tests to enable individualized diagnosis, prevention and treatment.
IntegraGen’s proprietary gene mapping technology GenomeHIP provides fast, reliable, and cost-effective discovery of genetic loci. Paired with strong biostatistics, bioinformatics and fine mapping genotyping capabilities, IntegraGen has successfully identified and patented genes associated with early and late onset diseases. Efforts are currently focused on Type-2 Diabetes, Obesity, Autism and Bi-Polar Disorder. Clinical trials for the company’s first genetic test for autism, based on internally identified genes, were carried out in Q1 2007.
Founded in July 2000, IntegraGen has 34 employees and is based in the French Genopole of Evry, near Paris, France, in Bonn, Germany and in New York, USA. More information can be found at www.integragen.com.
Illumina is a leading developer, manufacturer and marketer of next-generation life science tools and integrated systems for the large scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier and permit better choices of drugs for individual patients.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation with Affymetrix and our ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray(TM), VeraCode(TM) and Solexa(R) technologies and to deploy new gene expression and genotyping products and applications for our technology platforms, (iii) to manufacture robust micro arrays and Oligator(R) oligonucleotides, (iv) to integrate and scale our VeraCode technology, (v) to scale further oligo synthesis output and technology to satisfy market demand derived from our collaboration with Invitrogen, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.